Tonabersat_product_DataBase

Bioactivity

Tonabersat (SB-220453) is a gap-junction modulator. Tonabersat prevents inflammatory damage in the central nervous system[1][2][3].

Target

Gap-junction

Invitro

Tonabersat, a novel benzopyran derivative, inhibits cortical spreading depression (CSD) and therefore might be able to inhibit the early migraine mechanisms[1].

In Vivo

Treatment with Tonabersat (10 mg/kg) significantly inhibits progression of metastatic lesions. Addition of NSC 241240 to either agent profoundly inhibits brain metastasis[2].

Name

Tonabersat

CAS

175013-84-0

Formula

C20H19ClFNO4

Molar Mass

391.82

Appearance

Solid

Transport

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Reference

[1]. Silberstein SD, et al. Tonabersat, a gap-junction modulator: efficacy and safety in two randomized, placebo-controlled, dose-ranging studies of acute migraine. Cephalalgia. 2009 Nov;29 Suppl 2:17-27. [2]. Chen Q, et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature. 2016 May 18;533(7604):493-8. [3]. Kim Y, et al. Tonabersat Prevents Inflammatory Damage in the Central Nervous System by Blocking Connexin43 Hemichannels. Neurotherapeutics. 2017 May 30.

PeptideDB

Tonabersat

CAS: 175013-84-0 F: C20H19ClFNO4 W: 391.82